Multi-institutional study of Osimertinib dose-optimization in Non-small cell lung cancer patients with EGFR activating mutation aged 70 Years or older - Multi-institutional study of Osimertinib dose-optimization in Non-small cell lung cancer patients with EGFR activating mutation aged 70 Years or older(MONEY Trial)
Cohort Study to Evaluate the Efficacy and Safety of Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients with Muti-gene assay - N-SAS BC07 biomarker study (Trans-RESPECT)
An assessment of quality of life using electronic patient-reported outcome (ePRO) in patients receiving second-line chemotherapy for unresectable pancreatic cancer - QOL-ePAC
100 项与 Public Health Research Foundation 相关的临床结果
0 项与 Public Health Research Foundation 相关的专利（医药）
100 项与 Public Health Research Foundation 相关的药物交易
100 项与 Public Health Research Foundation 相关的转化医学
